InduPro raises $77M Series B, doses first patient in cancer trial
What's the deal? InduPro has closed a $77 million Series B financing and dosed the first patient in the Phase 1 study of IDP-001, its lead oncology programme. The round was led by The Column GroupDealroom has a profile for this one. Try Dealroom →, with participation from Vida VenturesDealroom has a profile for this one. Try Dealroom →, MRL VenturesDealroom has a profile for this one. Try Dealroom →, Emerson Collective, Euclidean CapitalDealroom has a profile for this one. Try Dealroom →, Solasta VenturesDealroom has a profile for this one. Try Dealroom →, SanofiDealroom has a profile for this one. Try Dealroom → and Eli LillyDealroom has a profile for this one. Try Dealroom →.
What's next? Proceeds will support Phase 1 development and early proof-of-concept work for IDP-001, a proximity-based bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen. The study is enrolling adults with advanced or metastatic non-small cell lung cancer and other solid tumours.
The signal: With its lead programme now in the clinic, InduPro is moving its proximity-guided approach from preclinical research into first-in-human testing across oncology indications.
Read more: Morningstar
Image credit: Generated with Gemini
